We are live on ! Find out more
BG

Bellevue Group Portfolio holdings

AUM $4.2B
1-Year Est. Return 54.85%
This Fund
S&P 500
This Quarter Est. Return
+11.61%
1 Year Est. Return
+54.85%
3 Year Est. Return
+140.3%
5 Year Est. Return
+171.01%
10 Year Est. Return
+915.55%
AUM
$1.17B
AUM Growth
+$164M
Cap. Flow
+$76.2M
Cap. Flow %
6.49%
Top 10 Hldgs %
32.39%
Holding
149
New
25
Increased
54
Reduced
51
Closed
11

Top Buys

Rank Stock Value
1
BMY icon
Bristol-Myers Squibb
BMY
+$11.9M
2
CI icon
Cigna
CI
+$11.9M
3
PRAH
PRA Health Sciences, Inc.
PRAH
+$11.1M
4
VTRS icon
Viatris
VTRS
+$10.5M
5
CELG
Celgene Corp
CELG
+$8.17M

Top Sells

Rank Stock Value
1
INCY icon
Incyte
INCY
+$12M
2
UNH icon
UnitedHealth
UNH
+$11M
3
ALGN icon
Align Technology
ALGN
+$9.05M
4
VRTX icon
Vertex Pharmaceuticals
VRTX
+$8.45M
5
IART icon
Integra LifeSciences
IART
+$8.23M

Sector Composition

Rank Sector Weight
1 Healthcare 93.53%
2 Industrials 0.76%
3 Technology 0.15%
4 Financials 0.11%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
WMGI
26
DELISTED
Wright Medical Group Inc
WMGI
$14.8M 1.26%
570,301
+28,500
+5% +$651K
BMY icon
27
Bristol-Myers Squibb
BMY
$124B
$14.4M 1.23%
260,849
+220,849
+552% +$11.9M
HOLX
28
DELISTED
Hologic
HOLX
$14.4M 1.23%
361,894
-122,000
-25% -$4.69M
KTWO
29
DELISTED
K2M Group Holdings, Inc
KTWO
$13.8M 1.18%
612,941
-55,000
-8% -$1.16M
WBA
30
DELISTED
Walgreens Boots Alliance
WBA
$13.6M 1.16%
226,018
-37,542
-14% -$2.42M
LH icon
31
Labcorp
LH
$23.2B
$13.5M 1.15%
87,579
+18,053
+26% +$2.73M
IONS icon
32
Ionis Pharmaceuticals
IONS
$8.99B
$13.4M 1.15%
322,586
+10,400
+3% +$461K
FIT
33
DELISTED
Fitbit, Inc. Class A common stock
FIT
$13.4M 1.15%
2,057,900
-237,500
-10% -$1.36M
MGNX icon
34
MacroGenics
MGNX
$285M
$12.3M 1.05%
596,913
+33,762
+6% +$760K
ESPR
35
DELISTED
Esperion Therapeutics
ESPR
$12.3M 1.05%
313,520
+140,800
+82% +$7.11M
PRAH
36
DELISTED
PRA Health Sciences, Inc.
PRAH
$12.1M 1.03%
+129,400
New +$11.1M
ALDR
37
DELISTED
Alder Biopharmaceuticals
ALDR
$12M 1.02%
758,964
+58,500
+8% +$889K
BIIB icon
38
Biogen
BIIB
$30.4B
$11.4M 0.97%
39,345
-6,855
-15% -$1.93M
GILD icon
39
Gilead Sciences
GILD
$167B
$11.4M 0.97%
160,300
-6,900
-4% -$487K
ABMD
40
DELISTED
Abiomed Inc
ABMD
$11.1M 0.94%
27,081
-169
-0.6% -$61.2K
SHPG
41
DELISTED
Shire pic
SHPG
$11M 0.94%
65,292
+6,857
+12% +$1.11M
LIVN icon
42
LivaNova
LIVN
$4.43B
$11M 0.94%
109,924
+15,200
+16% +$1.38M
ALNY icon
43
Alnylam Pharmaceuticals
ALNY
$35.7B
$10.2M 0.87%
103,500
+81,750
+376% +$8.11M
INSM icon
44
Insmed
INSM
$23.5B
$10M 0.86%
424,051
+89,562
+27% +$2.31M
HCM icon
45
HUTCHMED
HCM
$1.86B
$10M 0.85%
332,536
+30,116
+10% +$956K
AKCA
46
DELISTED
Akcea Therapeutics Inc
AKCA
$8.99M 0.77%
379,301
+330,502
+677% +$7.89M
AMGN icon
47
Amgen
AMGN
$198B
$8.84M 0.75%
47,900
-20,800
-30% -$3.68M
RMD icon
48
ResMed
RMD
$28.9B
$8.51M 0.73%
82,200
-24,800
-23% -$2.51M
ZBH icon
49
Zimmer Biomet
ZBH
$17.6B
$7.96M 0.68%
73,543
-11,947
-14% -$1.3M
GNMK
50
DELISTED
GenMark Diagnostics, Inc
GNMK
$7.57M 0.65%
1,186,502
– –
1
2
3 4 5

Similar funds

WSFS
Wilmington Savings Fund Society Wilmington, Delaware $4.2B AUM 18.37% 1-Year Est. Return
AC
AlphaCore Capital La Jolla, California $4.22B AUM 21.28% 1-Year Est. Return
HIP
HUB Investment Partners Austin, Texas $4.18B AUM 24.76% 1-Year Est. Return
DT
DV Trading Chicago, Illinois $4.22B AUM
ATPW
Ashton Thomas Private Wealth Scottsdale, Arizona $4.23B AUM 20.9% 1-Year Est. Return
BT
Banque Transatlantique Paris, France $4.17B AUM 28.5% 1-Year Est. Return
NCM
Nearwater Capital Markets Dublin 4, Dublin, Ireland $4.24B AUM 66.03% 1-Year Est. Return
MSU
Mizuho Securities USA New York $4.24B AUM 23.1% 1-Year Est. Return

Bellevue Group's Q2 2018 Portfolio in Review

As of Q2 2018, Bellevue Group held 149 positions worth $1.17B, up 16% from $1.01B the previous quarter. Its ten largest holdings account for 32% of the portfolio.

Bellevue Group deployed $76.2M of net new capital in Q2 2018, opening 25 new positions and adding to 54 existing holdings. Its largest new stake was PRA Health Sciences, Inc.: 129,400 shares worth $12.1M.

By sector, the portfolio is most concentrated in Healthcare at 94% of assets, down from 95% a quarter earlier, followed by Industrials and Technology.

On the sell side, the largest reduction was Incyte, an estimated $12M trimmed.

  • Bellevue Group's largest Q2 2018 buy was PRA Health Sciences, Inc.: 129,400 shares worth $12.1M.
  • Bellevue Group added most to Bristol-Myers Squibb in Q2 2018, an estimated $11.9M increase.
  • Bellevue Group's biggest Q2 2018 reduction was Incyte, cutting an estimated $12M.
  • Bellevue Group fully exited Perrigo in Q2 2018, selling an estimated $2.75M.
  • Bellevue Group's ten largest holdings make up 32% of its $1.17B portfolio in Q2 2018.
  • Bellevue Group opened 25 new positions and closed 11 in Q2 2018.
  • Bellevue Group's portfolio value rose 16% quarter-over-quarter to $1.17B.

Based on Bellevue Group's 13F filing for Q2 2018, filed 7 Aug 2018.